Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...
The collaboration between ten23 health and BD aims to commercialize the BD Libertas wearable injector for large-volume ...
Previously lecanemab was only approved as an SC injection for maintenance dosing, following an initial 18 month IV phase.
LEQEMBI is currently approved in 53 countries and regions and is under regulatory review in 7 countries. In August 2025, the US FDA approved LEQEMBI IQLIK 360 mg for weekly subcutaneous maintenance ...
The US regulator expects to issue a decision on Eisai's application for Leqembi Iqlik, which it has granted priority review, by May 24.
Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...
TORONTO -- An investigational subcutaneous autoinjector showed comparable efficacy and safety to the IV formulation of lecanemab (Leqembi) for maintenance treatment in early Alzheimer's disease, ...
Subcutaneous anifrolumab significantly reduces disease activity in patients with moderate to severe systemic lupus erythematosus.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results